Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.
A new immunotherapy for hepatocellular carcinoma (HCC) using Freund's adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed. In 16 patients with HCC and one patient with metastatic liver cancer receiving this therapy, decrease and suppression of reelevation of alpha-fetoprotein after therapy was observed. Disappearance of tumor thrombi of HCC in the main portal vein was observed in a patient, and decrease of carcinoembryonic antigen was also observed in a patient with metastatic liver cancer. The present therapy using Freund's adjuvant and IL-2 is likely to open a new avenue for the treatment of patients with advanced liver cancer.
Ito
T
T
First Department of Internal Medicine, Okayama University Medical School, Japan.
Ikeda
N
N
Sue
K
K
Ukida
M
M
Higashi
T
T
Okamoto
T
T
Ohsawa
T
T
Nouso
K
K
Watanabe
A
A
Tsuji
T
T
D015250:Aclarubicin / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D005620:Freund's Adjuvant / Q000627:therapeutic use*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007459:Iodized Oil / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D000509:alpha-Fetoproteins / Q000032:analysis
D007376:Interleukin-2; D008937:Mitomycins; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; D016685:Mitomycin; D015250:Aclarubicin; D007459:Iodized Oil; D005620:Freund's Adjuvant